Last reviewed · How we verify
Ameparomo (PAROMOMYCIN)
Paromomycin, also known as Ameparomo, is a small molecule antiprotozoal medication. It was originally developed and is currently owned by various companies. Paromomycin is used to treat acute and chronic intestinal amebiasis, as well as hepatic coma. The medication is off-patent and has multiple generic manufacturers. Key safety considerations include its low bioavailability and potential gastrointestinal side effects.
At a glance
| Generic name | PAROMOMYCIN |
|---|---|
| Drug class | Antiprotozoal |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1969 |
Approved indications
- Acute amebiasis
- Chronic intestinal amebiasis
- Hepatic coma
Common side effects
- Nausea
- Abdominal cramps
- Diarrhea
Key clinical trials
- Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) (PHASE3)
- LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study (PHASE2)
- A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
- Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults (NA)
- Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa (PHASE3)
- Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011) (PHASE2)
- A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3 (PHASE2)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ameparomo CI brief — competitive landscape report
- Ameparomo updates RSS · CI watch RSS